Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.
Am J Med. 2009 Jun;122(6 Suppl):S11-24
Authors: Gilbert MP, Pratley RE
This article aims to provide an overview of efficacy and safety data on glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus. Our goal is to differentiate the clinical profiles of GLP-1 receptor agonists and DPP-4 inhibitors, as well as the individual agents within each class. Additionally, we examine the utility of GLP-1 receptor agonists and DPP-4 inhibitors as these agents may be applied at different stages of type 2 diabetes therapy and discuss recently published clinical findings and their implications for treatment.
PMID: 19464424 [PubMed - in process]